Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 24: The ECLIPSE Trial
Author(s): Ajay J Kirtane Added: 1 year ago
TCT Conference 2024 - Routine use of orbital atherectomy system (OAS) did not improve minimal stent area (MSA) or target vessel failure (TVF) at one year compaared to conventional balloon angioplasty.Dr Ajay J Kirtane (Columbia University Medical Center and New York-Presbyterian Hospital, New York, US) joins us onsite at TCT Conference to discuss the findings from ECLIPSE (NCT03108456; Abbott… View more

Intervention
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 1 year ago

Anticoagulation
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 8 months ago

Anticoagulation

Prevention & Chronic Conditions
Consequences and Management of Excessive Ostial Stent Protrusion
Author(s): Arditya Damarkusuma Added: 1 year ago
In this video, Dr Arditya Damarkusuma (Universitas Gadjah Mada, ID) presents his case report on aorto-ostial lesions, recently published in ICR Journal.This case covers the restenosis of a markedly protruding stent at the right coronary ostium in a 54-year old man, and is unusual in its 10-year longevity. Intravascular ultrasound-guided in-stent restenosis intervention using a wire bumper… View more

Imaging & Diagnostics

Intervention
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19
Author(s): Andrea Di Lenarda , Nicola Ferri , Massimiliano Lanzafame , et al Added: 1 year ago

COVID-19

CV Disease in Special Populations
ACC 25: Optimizing DAPT Duration
Author(s): Hyo-Soo Kim Added: 10 months ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR… View more

Anticoagulation

Intervention
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 2 years ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
View from the Thoraxcenter: TCT 23 Late-breaking Science Wrap Up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 2 years ago
What are the top late-breaking trials from #TCT2023? TCT 2023 — Join interventional cardiologists, Prof Nicolas Van Mieghem and Dr Joost Daemen from the Thoraxcenter as they unpack the most impactful late-breaking clinical trials and science data from this year's Transcatheter Cardiovascular Therapeutics Conference. Dive into this practical and engaging discussion and learn more about the… View more

Intervention
View from the Thoraxcenter: TCT 23 Late-breaking Science Preview
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 2 years ago
What's hot at TCT 2023? In this episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) preview the late-breaking data presented at TCT 2023. With their dynamic analysis, these anticipated trials are placed in context, highlighting the real-world implications tied to the data releases. Top trials covered: 00:31 - 02:12: PARTNER 3 Low… View more

Intervention
EuroPCR 24: The ABILITY Study
Author(s): Roxana Mehran Added: 1 year ago
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary… View more

Intervention